循环microRNA-18a对前列腺癌的诊断价值分析

Analysis on the diagnostic value of circulating microRNA-18a for prostate cancer

目的:通过检测前列腺癌患者血清微小RNA-18a(miR-18a)的水平,探讨其在前列腺癌患者中的诊断价值。方法:收集50例前列腺癌患者,30例良性前列腺增生(BPH)患者,20例健康对照者的血液标本,通过定量逆转录聚合酶链反应(qRT-PCR)检测miR-18a水平。分析血清miR-18a水平与前列腺癌Gleason分级及TNM分期的关系。采用Spearman法分析血浆miR-210与肌钙蛋白T(cTnT)之间的相关性。采用ROC曲线分析miR-210对AMI早期诊断的价值。结果:前列腺癌组患者miR-18a的表达水平明显高于BPH组和正常对照组(均P<0.01);血清miR-18a与Gleason评分,肿瘤分期有关(均P<0.01);血清miR-18a与PSA之间呈正相关关系(r=0.673,P=0.000);ROC曲线分析结果显示,miR-18a的ROC曲线下面积(AUC)为0.911(95%CI:0.855~0.966,P=0.000),当miR-18a相对表达水平为3.35时,敏感度为86.0%,特异度为82.0%,阳性预测值82.7%,阴性预测值85.4%。结论:前列腺癌患者血清miR-18a表达水平增高,可能是前列腺癌诊断的潜在的新型生物标志物,有利于PC和BPH之间的鉴别。

Objective： To investigate the level of serum microRNA-18a（ miR-18a） in patients with prostate cancer,and to explore its diagnostic value for patients with prostate cancer. Methods： The serum levels of miR-18a were detected by quantitative reverse transcription polymerase chain reaction（ QRT-PCR） in 50 patients with prostate cancer,30 patients with benign prostatic hyperplasia（ BPH） and 20 healthy persons. The relationship between serum miR-18a level and Gleason grade and TNM staging of prostate cancer was analyzed. Correlation between miR-18a and PSA were analyzed by Spearman test. The ROC curve was used to analyze the diagnostic value of miR-18a in the diagnosis of prostate cancer. Results： The levels of serum miR-18a in patients with prostate cancer were obviously higher than that in BPH group and control group（ all P〈0. 01）. The level of serum miR-18a in prostate cancer was correlated with clinical TNM stage and Gleason pathologic grade（ all P〈0. 01）. The level of AGR2 was positively correlated with PSA（ r = 0. 673,P〈0. 01）. The area under curve（ AUC） for miR-18a was 0. 911（ 95% CI： 0. 855 ~ 0. 966,P = 0. 000）. When the relative expression level of miR-18a was 3. 35,the sensitivity was 86. 0%,the specificity was82. 0%,the positive predictive value was 82. 7% and the negative predictive value was 85. 4%. Conclusions： The level of serum miR-18a in prostate cancer is high,so MiR-18a may serve as a potential novel biomarker for the diagnosis of prostate cancerwhich facilitates discrimination between prostate cancer and BPH.